Drugs / Etavopivat
Trials 13
| Phase | Registry id | Dates | Indication | Sponsor | Status | Outcome |
|---|---|---|---|---|---|---|
| Phase 16 trials | ||||||
| Phase 1 | NCT07023029 | Jun → Sep 2025 | sickle cell disease, thalassemia | Novo Nordisk A/S | Completed | No outcome recorded |
| Phase 1 | NCT06813924 | Feb → May 2025 | inherited hemoglobinopathy | Novo Nordisk A/S | Completed | No outcome recorded |
| Phase 1 | NCT06581627 | Aug → Oct 2024 | sickle cell disease, thalassemia | Novo Nordisk A/S | Completed | No outcome recorded |
| Phase 1 | NCT06433661 | May → Jul 2024 | inherited hemoglobinopathy | Novo Nordisk A/S | Completed | No outcome recorded |
| Phase 1 | NCT06336018 | May 2024 → Aug 2025 | liver disorder | Novo Nordisk A/S | Completed | No outcome recorded |
| Phase 1 | NCT03815695 | Dec 2018 → Dec 2021 | sickle cell disease | Forma Therapeutics, Inc. | Completed | No outcome recorded |
| Phase 25 trials | ||||||
| Phase 2 | NCT05725902 | Mar 2024 → Mar 2026 | sickle cell disease | Novo Nordisk A/S | Completed | No outcome recorded |
| Phase 2 | NCT05953584 | Jun 2023 → Aug 2027 expected | sickle cell disease | Forma Therapeutics, Inc. | Recruiting | No outcome recorded |
| Phase 2 | NCT06198712 | Jan 2023 → Feb 2028 expected | sickle cell disease | Forma Therapeutics, Inc. | Recruiting | No outcome recorded |
| Phase 2 | NCT05568225 | Nov 2022 → Jul 2024 | — | Forma Therapeutics, Inc. | Terminated | No outcome recorded |
| Phase 2 | NCT04987489 | Mar 2022 → Sep 2025 | sickle cell disease, thalassemia | Forma Therapeutics, Inc. | Completed | No outcome recorded |
| Phase 32 trials · 1 met primary | ||||||
| Phase 3 | NCT06612268 | Feb 2025 → Aug 2027 expected | sickle cell disease | Novo Nordisk A/S | Recruiting | No outcome recorded |
| Phase 3 | NCT04624659 | Jan 2021 → Feb 2026 overdue | sickle cell disease | Forma Therapeutics, Inc. | Active not recruiting | Met primary |
News releases announcing trial results or a regulatory action · 1
| Date | Issuer | Release |
|---|---|---|
| 2026-04-20 | Novo Nordisk A/S | Results Novo Nordisk: Etavopivat is the first in a new class of drugs to meet both co-primary endpoints in the phase 3 HIBISCUS trial, substantially reducing vaso-occlusive crisis events and improving haemoglobin response in sickle cell disease novonordisk.com ↗
Novo Nordisk today announced the topline results from HIBISCUS, a pivotal phase 3 trial of once-daily oral etavopivat in adults and adolescents with sickle cell disease (SCD). |
All press releases naming this drug 1 release
Evidence & citations 6 cited values
Every value below carries the sentence it was read from. 15 sources stand behind the page.
| Field | Value | Cited text |
|---|---|---|
| Known as | Etavopivat | ClinicalTrials.gov intervention name — accepted as the source's own label NCT07023029 ↗ |
| Known as | FT-4202 | ClinicalTrials.gov intervention name — accepted as the source's own label NCT03815695 ↗ |
| Action | Activate | “Etavopivat (FT-4202) is an orally administered, small-molecule allosteric activator of erythrocyte pyruvate kinase-R (PKR) in clinical development for the treatment of sickle...” PMID 35019238 ↗ Jan 20221“Pyruvate kinase isozymes R/L activator” CHEMBL4650332 ↗ |
| Modality | Small molecule | “Etavopivat (FT-4202) is an orally administered, small-molecule allosteric activator of erythrocyte pyruvate kinase-R (PKR) in clinical development for the treatment of sickle...” PMID 35019238 ↗ Jan 2022 |
| Route | Oral | “Etavopivat (FT-4202) is an orally administered, small-molecule allosteric activator of erythrocyte pyruvate kinase-R (PKR) in clinical development for the treatment of sickle...” PMID 35019238 ↗ Jan 2022 |
| Target | PKLR | “Pyruvate kinase isozymes R/L activator” CHEMBL4650332 ↗ |